NCT03095105View on ClinicalTrials.gov

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 24, 2006

Primary Completion Date

March 2, 2006

Study Completion Date

March 2, 2006

Conditions
Parkinson Disease
Interventions
DRUG

200 mg BIA 6-512

capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture

Trial Locations (1)

D-22525

Scope International AG, Hamburg

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT03095105 - Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects | Biotech Hunter | Biotech Hunter